Compound Profile: Viropil 50/300/
Viropil 50/300/300 mg is an antiretroviral combination pharmaceutical formulation containing efavirenz 50mg, emtricitabine 300mg, and tenofovir disoproxil fumarate 300mg, manufactured by Emcure Pharmaceuticals Ltd. This fixed-dose combination represents a triple-drug antiretroviral therapy formulation commonly investigated in HIV treatment research. The formulation combines a non-nucleoside reverse transcriptase inhibitor (efavirenz) with two nucleoside reverse transcriptase inhibitors (emtricitabine and tenofovir disoproxil fumarate), providing researchers with a comprehensive antiretroviral system for laboratory studies examining HIV viral suppression mechanisms and resistance development patterns.
Laboratory Applications
Research scientists examine Viropil combinations to study HIV reverse transcriptase inhibition mechanisms, viral load suppression kinetics, and resistance mutation emergence in cell culture models. The three-drug formulation allows investigators to analyse synergistic effects between different classes of antiretroviral compounds in viral replication studies. Laboratory applications include examining efavirenz-mediated allosteric inhibition of HIV-1 reverse transcriptase, evaluating emtricitabine’s cytosine analogue incorporation mechanisms, and investigating tenofovir’s adenosine analogue chain termination effects. Researchers at Stroid UK Shop utilise these formulations alongside compounds from our pharmaceutical research collection, complementing studies involving selective androgen receptor modulators and research peptides in comprehensive biochemical investigations.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Components | Efavirenz 50mg, Emtricitabine 300mg, TDF 300mg |
| Manufacturer | Emcure Pharmaceuticals Ltd. |
| Dosage Form | Film-coated tablet |
| CAS Numbers | Efavirenz: 154598-52-4, Emtricitabine: 143491-57-0, TDF: 147127-20-6 |
| Storage Requirements | Room temperature, dry conditions |
| Research Grade | Pharmaceutical standard |
Research Compliance
Viropil 50/300/300 mg by Emcure Pharmaceuticals is supplied exclusively for in-vitro research purposes and laboratory investigations. This pharmaceutical combination is not intended for human consumption, clinical administration, or therapeutic applications. Researchers must ensure appropriate laboratory safety protocols and regulatory compliance when handling antiretroviral compounds in research environments.
